In people with relapsing forms of multiple sclerosis (MS) treated with Ocrevus (ocrelizumab), levels of B-cells can help to predict the risk of progression independent of relapse activity, a new study reports. “Our results unveil a discernible relationship between the degree of B-cell depletion and disease progression in…
treatment
Injections of methotrexate into the spinal canal given every three months were safe and well tolerated, and helped adults with progressive forms of multiple sclerosis (MS) maintain stable disease levels for up to nine years. That’s according to data from a small, open-label Phase 1 clinical study (NCT02644044)…
Foralumab was well tolerated in people with nonactive secondary progressive multiple sclerosis (SPMS), according to data from a small, open-label study conducted under an expanded access program. The therapy, being developed by Tiziana Life Sciences, also eased fatigue and lessened disability in some participants. The promising findings formed…
Wider rims of immune cells surrounding multiple sclerosis (MS) lesions in the brain and spinal cord are associated with faster disease progression, a new study shows. Monitoring this type of lesion may help track MS disease progression and measure how the disease is responding to treatment, and the…
Vidofludimus calcium, an experimental oral therapy from Immunic Therapeutics, reduced the risk of confirmed disability worsening and slowed brain shrinkage in people with progressive forms of multiple sclerosis (MS). That’s according to top-line data from CALLIPER (NCT05054140), a Phase 2 clinical trial testing a daily dose of…
Octave Bioscience’s Multiple Sclerosis Disease Activity (MSDA) test, which uses data from blood biomarkers to assess multiple sclerosis (MS) disease activity, is now available across all 50 U.S. states to help guide clinicians’ decisions about care. Octave said the test received certification from the New York State Clinical…
The Patient-Centered Outcomes Research Institute (PCORI) has awarded the Cleveland Clinic $6.7 million to identify optimal treatment strategies for people with relapsing-remitting multiple sclerosis (RRMS). The funds will support the extension study of the multicenter DELIVER-MS (NCT03535298) clinical trial. The study is comparing two MS treatment approaches…
Bionxt Solutions is getting ready to launch a pilot clinical trial to test BNT23001, its sublingual (under-the-tongue) version of cladribine to treat multiple sclerosis (MS). The treatment would be an alternative to Mavenclad, the approved tablet form of cladribine. Bionxt‘s thin-film formulation quickly dissolves under the tongue,…
Early treatment with Ocrevus (ocrelizumab) may help protect the cerebellum, a region of the brain that plays a key role in motor coordination, cognitive function, and emotional regulation, from damage in people with multiple sclerosis (MS), a study suggested. Data from the clinical studies that supported Ocrevus’ approval…
New diagnostic criteria and biomarkers, how to manage MS in older patients and children, and vaccine recommendations are among topics covered in a new set of guidelines for best practices in multiple sclerosis (MS) care. The Consortium of Multiple Sclerosis Centers, a network of more than 15,000 clinicians…
An online training program for managing memory and cognitive difficulties may help people with multiple sclerosis (MS), a study suggests. The program, delivered entirely through virtual sessions, taught participants practical strategies to boost memory then guided them about using the techniques in real-world situations, such as organizing errands, planning…
Assessing multiple sclerosis (MS) disease activity using Octave Bioscience’s MS Disease Activity (MSDA) blood biomarker test can help guide clinicians’ decisions about care, a study showed. “Our goal is to empower both providers and patients with precision tools that transform MS care,” Doug Biehn, CEO of Octave, said…
One year of Tysabri (natalizumab) treatment improves working ability among people with relapsing-remitting multiple sclerosis (RRMS), according to new data from TITAN, an observational study by researchers in France that assessed the impact of the infusion therapy. Use of the approved therapy resulted in improvements across several parameters:…
Rituximab, sometimes used off-label as a multiple sclerosis (MS) treatment, may be as effective — at a much lower cost to patients — as the approved therapy Ocrevus (ocrelizumab) at managing relapsing forms of the disease, a new study from Egypt suggests. The study’s results showed that the…
People with multiple sclerosis (MS) who live in rural areas are 17% less likely to receive disease-modifying therapies (DMTs) than those in urban regions, a study involving people from the Canadian province of Alberta suggested. The likelihood was lower when considering therapies that are highly effective at controlling…
Biostate AI is partnering with the nonprofit Accelerated Cure Project (ACP) to develop a series of artificial intelligence (AI) models that can predict multiple sclerosis (MS) progression and how patients may respond to treatment. As part of the partnership, Biostate AI will use its high-throughput technology to…
Medicaid coverage for people with multiple sclerosis (MS) in the U.S. is associated with worse disease outcomes — including more clinical relapses and greater disability progression — compared with private insurance, according to a new study that investigated the impact of insurance type and socioeconomic factors on patient care. In…
A single 600 mg dose of Briumvi (ublituximab-xiiy) — instead of the approved 150 mg initial dose plus a 450 mg dose two weeks later — was well tolerated by adults with relapsing forms of multiple sclerosis (MS). That’s according to new data from the ENHANCE Phase…
From 2019 to 2023, people with relapsing-remitting multiple sclerosis (RRMS) in France on treatment with Tysabri (natalizumab) adopted more at-home dosing and longer periods between doses, according to a review by researchers of the French national hospital database. An increasing use of the therapy during…
Kyverna Therapeutics’ CAR T-cell therapy candidate KYV-101 was deemed safe and well tolerated, and showed preliminary signs of efficacy, in people with progressive forms of multiple sclerosis (MS) in clinical testing. That’s according to data from two investigator-initiated Phase 1 trials, which enrolled individuals with secondary progressive…
A pair of scientists have been awarded a 2025 Breakthrough Prize in Life Sciences for their work uncovering factors that give rise to multiple sclerosis (MS), paving the way for new therapeutic developments. Sometimes referred to as the “Oscars of Science,” Breakthrough Prizes are given each year to…
Frexalimab, an experimental antibody-based medication, was well tolerated and maintained disease control over two years in adults with relapsing forms of multiple sclerosis (MS). That’s according to new data from an open-label extension to a Phase 2 clinical trial (NCT04879628) in which frexalimab outperformed a placebo at reducing…
Clinical improvements in vision and cognition linked to the use of treatment candidate CNM-Au8 were correlated with signs of nerve cell repair and remyelination among people with relapsing-remitting multiple sclerosis (RRMS), according to new data. Remyelination is the process by which myelin, the fatty substance surrounding nerve cells…
Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo, by 31%, in people with nonrelapsing secondary progressive multiple sclerosis (SPMS). That’s according to recently published data from the HERCULES Phase 3 trial (NCT04411641), where the experimental therapy…
A Phase 4 observational study called ENABLE is enrolling adults with relapsing forms of multiple sclerosis (MS) across the U.S. to better understand the safety, tolerability, and efficacy of Briumvi (ublituximab-xiiy) in the real world. At least 500 patients are expected to enter ENABLE (NCT06433752) at some…
Treatment during pregnancy with the approved multiple sclerosis (MS) medication Copaxone (glatiramer acetate injection) does not appear to increase the risk of birth defects in infants, and its use while breastfeeding is not linked to growth problems in the youngsters, according to follow-up data of mothers and their children…
Fibrobiologics’ investigational cell therapy CYMS101 can significantly increase myelin production and promote myelin repair in a mouse model of multiple sclerosis (MS), the company has announced. The experimental therapy, which is made of connective tissue cells called fibroblasts, demonstrated benefits within seven weeks after both single and multiple infusions…
People with multiple sclerosis (MS) may receive less frequent infusions of rituximab without increasing their chances of relapse or disease progression, according to a real-world study from Norway. After receiving three doses at six-month intervals, extending the time between following doses to nine months is “a safe and effective…
A small molecule that blocks the activity of a protein called TYK2 in the brain showed promise at reducing disease activity in mouse models of multiple sclerosis (MS), according to a study. The study was conducted by Neuron23, which is advancing a small molecule TYK2 inhibitor called NEU-627…
The AdventHealth Neuroscience Institute is recruiting patients for a Phase 1b clinical trial testing IDP-023, an off-the-shelf cell-based treatment that Indapta Therapeutics is developing for primary or nonactive secondary progressive multiple sclerosis (MS). The company delayed the study’s expected launch in the second half of last…